Resources
27 Results (showing 11 - 20)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 11/10/2020 (updated 4/3/2024)
In the context of the trends in Oregon SUD metrics and the increasing infectious complications related to IDU in other jurisdictions and their implications for HIV and HCV transmission, we sought to 1) describe statewide trends in IDU-related serious bacterial infections (SBI) hospitalizations overall and by SBI type and drug use diagnosis, 2) assess IDU-related SBI diagnoses among individuals living with HIV and HCV, and 3) and determine the annual costs of IDU-related SBI overall and by SBI type.
Posted 11/4/2020 (updated 4/3/2024)
The opioid crisis has disproportionally affected Appalachia. One of the potentially
lethal and costly complications associated with IV drug use is infective endocarditis (IE). The goal of this study was to assess the trend and costs of substance abuse associated IE admissions in Southern West Virginia.
Posted 8/19/2021 (updated 4/2/2024)
In spring 2021, pharmaceutical manufacturers and distributors notified syringe services programs (SSPs) and partners that there would be significant interruptions in the supply of injectable/intramuscular (IM) naloxone. Currently, production and distribution delays are expected to last until fall 2021. This will specifically affect SSPs because IM naloxone is the most affordable formulation, and therefore is most commonly utilized by programs that distribute large volumes of naloxone to reduce fatal overdose rates.
Posted 8/4/2021 (updated 4/2/2024)
Expanding The Circle of Care: A Practical Guide to Syringe Services for Tribal and Rural Communities
Posted 8/3/2021 (updated 4/2/2024)
This guide presents practical information on establishing and maintaining syringe services in rural and tribal communities based on experiences of the Bad River Band of Lake Superior Chippewa.
Posted 7/7/2021 (updated 4/2/2024)
Background: Injecting drug users (IDUs) are at increased risk of acquiring and transmitting HIV and other bloodborne pathogens through the multi-person use of syringes. Although research has shown that increased access to syringes through syringe exchange programs (SEPs) is an effective strategy to reduce risky injection practices many areas of the United States still do not have SEPs. In the absence of SEPs, legislation allowing pharmacies over-the-counter sales of syringes has also been shown to reduce syringe sharing. The success of pharmacy sales however is limited by other legal stipulations, such as drug paraphernalia laws, which in turn may contribute to fear among IDUs about being caught purchasing and carrying syringes.
Posted 10/12/2020 (updated 3/29/2024)
This article discusses findings from a study published in the Journal of Viral Hepatitis which addresses the question of HCV testing frequency in people who inject drugs.
Posted 10/5/2020 (updated 3/29/2024)
This review looks at evidence and program models for alternatives to hospitalization to treat serious infections in people who inject drugs.
Posted 9/18/2020 (updated 3/29/2024)
The National Alliance of State and Territorial AIDS Directors (NASTAD) hosted the Hepatitis A and Hepatitis B Vaccination Efforts in People Who Inject Drugs webinar last week, September 10, 2020. The session featured Centers for Disease Control and Prevention subject matter experts who discussed the epidemiology of hepatitis A and hepatitis B in people who use and inject drugs and the rationale for the vaccination recommendations. The session also featured several jurisdictions and partner organizations who shared their lessons learned and best practices for reaching and implementing vaccination services in this community.
Posted 12/4/2019 (updated 3/28/2024)
To focus national and local prevention efforts on eliminating HIV, CDC analyzed surveillance, pharmacy, and other data to determine the status of these strategies (diagnose, treat, and prevent HIV infections) at the national and state levels.